Media stories about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat negative recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a daily sentiment score of -0.07 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.4452094233042 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Madrigal Pharmaceuticals (MDGL) Releases Earnings Results (americanbankingnews.com)
- ADXS Continues To Slide, MDGL To Report NASH Data In Q2, Keep An Eye On RXII (markets.businessinsider.com)
- BRIEF-Madrigal Pharmaceuticals Qtrly Loss Per Share $0.67 (reuters.com)
- Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 (finance.yahoo.com)
- Vascular Disrupting Agents Market Latest Report with Forecast to 2025 (openpr.com)
Several brokerages have weighed in on MDGL. Zacks Investment Research downgraded shares of Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Roth Capital lifted their price objective on shares of Madrigal Pharmaceuticals from $170.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, February 9th. JMP Securities lifted their price objective on shares of Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, December 6th. Evercore ISI restated an “outperform” rating and issued a $175.00 price target (up previously from $140.00) on shares of Madrigal Pharmaceuticals in a research report on Thursday, February 8th. Finally, HC Wainwright boosted their price target on shares of Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Madrigal Pharmaceuticals currently has an average rating of “Buy” and an average price target of $154.20.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.67) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.03. sell-side analysts predict that Madrigal Pharmaceuticals will post -2.57 EPS for the current fiscal year.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.